Macrophage Depletion by Clodronate Attenuates Bone Morphogenetic Protein-7 Induced M2 Macrophage Differentiation and Improved Systolic Blood Velocity in Atherosclerosis
Overview
Affiliations
Bone morphogenetic protein-7 (BMP-7) affects the presence of macrophage subtypes in vitro and in vivo at an early stage of atherosclerosis (ATH); however, it remains unknown whether BMP-7 treatment affects the development and progression of ATH at a mid-stage of the disease. We therefore performed a Day 28 (D28) study to examine BMP-7's potential to affect monocyte differentiation. Atherosclerosis was developed in ApoE KO mice, and these animals were treated with intravenous injections of BMP-7 and/or liposomal clodronate (LC). BMP-7 significantly (P < 0.05) lowers plaque formation following induction of atherosclerosis. However, upon macrophage depletion, BMP-7 fails to significantly alter plaque progression suggesting a direct role of BMP-7 on macrophages. Immunohistochemical staining of carotid arteries was performed to determine BMP-7's effect on pro-inflammatory M1 inducible nitric oxide synthase and anti-inflammatory M2 (cluster of differentiation [CD]206, Arginase-1) macrophages, and monocytes ( CD14). BMP-7 significantly reduced pro-inflammatory M1 macrophages and increased anti-inflammatory M2 macrophages at D28, while BMP-7 showed no effect on M2 macrophage differentiation in animals treated with LC. Enzyme-linked immunosorbent assay data showed significant reduction in proinflammatory cytokines (Interleukin-6 [IL-6]), monocyte chemoattractant protein-1, and tumor necrosis factor-α) and a significant increase in anti-inflammatory cytokine (IL-10) in BMP-7 treated mice (P < 0.05).Western blot analysis of arterial tissue confirms a significant increase in pro-survival kinases extracellular-signal regulated kinase and SMAD and a reduction in pro-inflammatory kinases p38 and c-Jun N-terminal kinase in BMP-7 treated mice (P < 0.05). Overall, this study suggests that clodronate treatment inhibits BMP-7 induced differentiation of monocytes into M2 macrophages and improved systolic blood velocity.
Da Silva J, Figueiredo A, Tseng Y, Carvalho E, Leal E Int J Mol Sci. 2025; 26(5).
PMID: 40076659 PMC: 11900347. DOI: 10.3390/ijms26052036.
Zhao J, Luo Y, Zhang L, Chen Y, Chen Y, Wu X Adv Sci (Weinh). 2024; 12(8):e2409882.
PMID: 39738868 PMC: 11848644. DOI: 10.1002/advs.202409882.
Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets.
Chen R, Zhang H, Tang B, Luo Y, Yang Y, Zhong X Signal Transduct Target Ther. 2024; 9(1):130.
PMID: 38816371 PMC: 11139930. DOI: 10.1038/s41392-024-01840-1.
Macrophage-based therapeutic approaches for cardiovascular diseases.
Sansonetti M, Al Soodi B, Thum T, Jung M Basic Res Cardiol. 2024; 119(1):1-33.
PMID: 38170281 PMC: 10837257. DOI: 10.1007/s00395-023-01027-9.
Sun W, Qu S, Ji M, Sun Y, Hu B Heliyon. 2023; 9(9):e19934.
PMID: 37809369 PMC: 10559348. DOI: 10.1016/j.heliyon.2023.e19934.